Immucell (ICCC) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Powered by 
Analysis
Immucell (ICCC) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.57 Bn | 40.38 Bn | 779.09 Mn | 15.11% |
| 2 | Zoetis | 30.57 Bn | 28.90 Bn | 1.05 Bn | -5.04% |
| 3 | Elanco Animal Health | 11.47 Bn | 10.94 Bn | 798.00 Mn | 390.91% |
| 4 | Phibro Animal Health | 1.43 Bn | 1.35 Bn | 134.40 Mn | 74.08% |
| 5 | Immucell | 87.38 Mn | 78.52 Mn | 2.44 Mn | 265.56% |
| 6 | Zhengye Biotechnology Holding | 64.40 Mn | 57.30 Mn | - | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - | -14.07% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 265.56% |
| Dec 31, 2025 | -368.77% |
| Sep 30, 2025 | 80.08% |
| Jun 30, 2025 | 132.77% |
| Mar 31, 2025 | 430.46% |
| Dec 31, 2024 | 1,175.19% |
| Sep 30, 2024 | 25.35% |
| Jun 30, 2024 | -11.01% |
| Mar 31, 2024 | 81.09% |
| Dec 31, 2023 | 106.72% |
| Sep 30, 2023 | -43.49% |
| Jun 30, 2023 | -44.01% |
| Mar 31, 2023 | -414.69% |
| Dec 31, 2022 | -1,263.52% |
| Sep 30, 2022 | -543.33% |
| Jun 30, 2022 | -778.92% |
| Mar 31, 2022 | 266.70% |
| Dec 31, 2021 | 356.88% |
| Sep 30, 2021 | 145.76% |
| Jun 30, 2021 | 118.43% |